Biodexa Pharmaceuticals (BDRX) Restructuring Costs (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Restructuring Costs data on file, last reported at -$3.2 million in Q2 2025.

• For the quarter ending Q2 2025, Restructuring Costs changed N/A year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2025 stood at -$10.8 million (changed N/A YoY), and the FY2025 full-year result was -$6.4 million, down 30.98% from the prior year.
• Restructuring Costs eased to -$3.2 million in Q2 2025, from -$2.6 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of -$2.2 million in Q4 2022 to a low of -$3.2 million in Q2 2025.
• A 5-year average of -$2.5 million and a median of -$2.3 million in 2022 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs jumped 65.86% in 2021 and declined 0.59% in 2022, its largest moves.
• Tracing BDRX's Restructuring Costs over 5 years: stood at -$2.2 million in 2021, then grew by 2.85% to -$2.2 million in 2022, then slumped by 32.19% to -$2.9 million in 2023, then gained by 8.94% to -$2.6 million in 2024, then decreased by 21.52% to -$3.2 million in 2025.
• Business Quant data shows BDRX's Restructuring Costs at -$3.2 million in Q2 2025, -$2.6 million in Q4 2024, and -$2.9 million in Q2 2023.